Amylyx Pharmaceuticals (AMLX) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition of avexitide, a first-in-class GLP-1 receptor antagonist, targets high unmet needs in hyperinsulinemic hypoglycemia, especially post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism, aligning with a focus on rare endocrine and neuroscience disorders.

• Avexitide expands the pipeline beyond neurodegenerative diseases, complementing programs in Wolfram syndrome, progressive supranuclear palsy, and ALS.

• The asset holds FDA Breakthrough Therapy Designation for PBH and congenital hyperinsulinism, and Orphan Drug Designation for hyperinsulinemic hypoglycemia.

• Addresses sizable orphan indications with no approved treatments, supporting long-term growth and leadership in rare endocrine disorders.

Financial terms and conditions

• Amylyx acquired avexitide from Eiger BioPharmaceuticals for $35.1 million in cash, plus assumed liabilities and cure costs.

• The deal includes a 3% royalty on future avexitide sales in PBH, tied to an academic license.

• Patent protection extends through 2037, with potential for further extension and additional exclusivity.

• Amylyx had $373.3 million in cash, cash equivalents, and short-term investments as of March 31, 2024.

Synergies and expected cost savings

• Acquisition leverages Amylyx's existing clinical, regulatory, and commercial infrastructure, expediting avexitide's development and commercialization.

• Builds on established relationships with physician and community experts, enhancing R&D capabilities and pipeline efficiency.